Prevalence of chemotherapy-induced peripheral neuropathy in cancer patients in a tertiary care hospital of Mexico
Abstract
Objective: To determine the prevalence of chemotherapy-induced peripheral neuropathy in cancer patients in a tertiary care hospital of Mexico.
Design: A retrospective, cross-sectional, observational and descriptive study conducted from January 2018, to December 2022, by review of patients' medical records.
Main outcome measures: Identify the most associated oncologic diagnosis, chemotherapeutic agents, main clinical manifestations, pain intensity and the most frequently used therapeutic drugs. Descriptive data analysis was performed.
Results: A total of 250 patients were enrolled in this retrospective study, representing 29.65% of those treated at the Pain Clinic.. The mean age was 59 ± 11.3 years, and 84.4% were female. The most frequent diagnosis was breast cancer (n=126, 50.4%). Paresthesia was identified as the main symptom (53.2%). Paclitaxel was the chemotherapeutic agent most commonly used (55.2%), and pregabalin was the most prescribed treatment (39.6%). Fatigue was the most frequent comorbid symptom (26.4%, n=66).
Conclusion: The prevalence found was similar than reported in different studies. The distribution of sex, age, commonly used chemotherapeutic agents, and neuromodulatory treatment was similar to reports from other countries. The findings highlight the need for patient education and medical staff training to identify early signs of neuropathy and ensure timely referrals.
Keywords: Cancer pain, chronic pain, chemotherapy-induced peripheral neuropathy
Keywords:
Cancer pain, Chronic Pain, chemotherapy-induced peripheral neuropathyDOI
https://doi.org/10.22270/jddt.v15i3.7048References
1. Snijders RAH, Brom L, Theunissen M, van den Beuken-van Everdingen MHJ. Update on prevalence of pain in patients with cancer 2022: A systematic literature review and meta-analysis. Cancers (Basel). 2023;15(3):591. DOI: http://dx.doi.org/10.3390/cancers15030591
2. Evenepoel M, Haenen V, De Baerdemaecker T, Meeus M, Devoogdt N, Dams L, et al. Pain prevalence during cancer treatment: A systematic review and meta-analysis. J Pain Symptom Manage. 2022;63(3):e317–35. DOI: http://dx.doi.org/10.1016/j.jpainsymman.2021.09.011
3. Zhang S. “Chemotherapy-induced peripheral neuropathy and rehabilitation: A review.” Semin Oncol, 2021;48(3): 193-207. DOI: http://dx.doi.org/10.1053/j.seminoncol.2021.09.004
4. Kachrani R, Santana A, Rogala B, Pawasauskas J. Chemotherapy-induced peripheral neuropathy: Causative agents, preventative strategies, and treatment approaches. J Pain Palliat Care Pharmacother. 2020;34(3):141–52. DOI: http://dx.doi.org/10.1080/15360288.2020.1734144
5. Jones MR, Urits I, Wolf J, Corrigan D, Colburn L, Peterson E, et al. Drug-Induced Peripheral Neuropathy: A narrative review. Curr Clin Pharmacol. 2020;15(1):38–48. DOI: http://dx.doi.org/10.2174/1574884714666190121154813
6. Bae EH, Greenwald MK, Schwartz AG. Chemotherapy-induced peripheral neuropathy: Mechanisms and therapeutic avenues. Neurotherapeutics [Internet]. 2021;18(4):2384–96. DOI: http://dx.doi.org/10.1007/s13311-021-01142-2
7. Kober KM, Olshen A, Conley YP, Schumacher M, Topp K, Smoot B, et al. Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel-induced peripheral neuropathy in breast cancer survivors. Mol Pain [Internet]. 2018;14:1744806918816462. Available from: http://dx.doi.org/10.1177/1744806918816462
8. Viatchenko-Karpinski V, Ling J, Gu JG. Down-regulation of Kv4.3 channels and a-type K+ currents in V2 trigeminal ganglion neurons of rats following oxaliplatin treatment. Mol Pain [Internet]. 2018;14:1744806917750995. Available from: http://dx.doi.org/10.1177/1744806917750995
9. Cavaletti G, Alberti P, Argyriou AA, Lustberg M, Staff NP, Tamburin S, et al. Chemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue. J Peripher Nerv Syst [Internet]. 2019;24 Suppl 2(S2):S6–12. Available from: http://dx.doi.org/10.1111/jns.12337
10. Desforges AD, Hebert CM, Spence AL, Reid B, Dhaibar HA, Cruz-Topete D, et al. Treatment and diagnosis of chemotherapy-induced peripheral neuropathy: An update. Biomed Pharmacother. 2022;147(112671):112671. DOI: http://dx.doi.org/10.1016/j.biopha.2022.112671
11. Hou S, Huh B, Kim HK, Kim KH, Abdi S. Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Recommendations. Pain Physician. 2018;21(6):571-592.
12. Morawska M, Grzasko N, Kostyra M, Wojciechowicz J, Hus M. Therapy-related peripheral neuropathy in multiple myeloma patients: Peripheral neuropathy in MM patients. Hematol Oncol [Internet]. 2015;33(4):113–9. Available from: http://dx.doi.org/10.1002/hon.2149
13. Kim B-S, Jin J-Y, Kwon JH, Woo IS, Ko YH, Park S-Y, et al. Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea. Asia Pac J Clin Oncol [Internet]. 2018;14(5):e448–54. Available from: http://dx.doi.org/10.1111/ajco.12822
14. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain [Internet]. 2014;155(12):2461–70. Available from: http://dx.doi.org/10.1016/j.pain.2014.09.020
15. Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, et al. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. BMC Cancer [Internet]. 2019;19(1):132. Available from: http://dx.doi.org/10.1186/s12885-019-5302-4
16. Burgess J, Ferdousi M, Gosal D, Boon C, Matsumoto K, Marshall A, et al. Chemotherapy-induced peripheral neuropathy: Epidemiology, pathomechanisms and treatment. Oncol Ther [Internet]. 2021;9(2):385–450. Available from: http://dx.doi.org/10.1007/s40487-021-00168-y
17. Park SB, Kwok JB, Asher R, Lee CK, Beale P, Selle F, et al. Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinician-reported incidence and severity of neurotoxicity in the ICON7 trial. Ann Oncol [Internet]. 2017;28(11):2733–40. Available from: http://dx.doi.org/10.1093/annonc/mdx491
18. Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol [Internet]. 2014;32(18):1941–67. Available from: http://dx.doi.org/10.1200/JCO.2013.54.0914
Published
Abstract Display: 234 
PDF Downloads: 305 PDF Downloads: 34 How to Cite
Issue
Section
Copyright (c) 2025 Karen Patricia Segovia Sandoval, Maria del Rocio Guillen-Nuñez, Angel Manuel Juarez-Lemus, Tania Helaine Ahuactzin Avendaño, Ana Lady Sanchez Ortega, Frida Paola Viveros Aguilar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.